Given the high rate of distant spread, effective systemic therapy is key to improving survival in patients with colorectal cancer (CRC). The past 40 years have seen progress. The addition of folinic acid (FA) to 5-fluorouracil (5-FU), the use of infusional rather than bolus 5-FU, and the combination of new active agents such as irinotecan and oxaliplatin with 5-FU/FA have each led to an increase in activity. In trials of current combination regimens first-line, response rates (RRs) in excess of 50% and median survival durations longer than 16 months are seen. A recent controlled trial suggests that overall time to progression is maximized and toxicity minimized when an irinotecan/5-FU/FA combination is used first-line, followed by an oxaliplatin/ 5-FU/FA combination on progression. In the adjuvant setting, 5-FU/FA is the standard of care in stage III disease but of uncertain value in stage II patients. The role of new agents such as irinotecan in adjuvant regimens is being assessed. Use of highly active chemotherapy in patients with unresectable disease (particularly liver metastases) achieves responses that allow a subset of patients to proceed to potentially curative surgery. The emergence of novel agents targeted at processes such as tumor angiogenesis will complement cytotoxic chemotherapy, while improved understanding of tumor biology should enable agents to be selected according to the likely sensitivity of the disease in a particular patient. In gastric cancer also, surgery remains the only potentially curative treatment. The extent of dissection required is debated, as is the potential benefit of adjuvant chemoradiotherapy (indeed the degree of resection may interact with the effect of adjuvant treatment). In untreated metastatic gastric cancer, median survival is 3-4 months. This can be increased to around 10 months using chemotherapy. Quality of life is also enhanced. There is no clearly defined standard of care. However, some form of cisplatin/5-FU combination can serve as a reference regimen. As single agents, both irinotecan and docetaxel achieve RRs of around 20% in metastatic CRC. In combination with cisplatin and/ or 5-FU a very high and promising RR is achieved. The promise of these agents in combination with 5-FU and 5-FU plus cisplatin is currently being tested in phase III trials.
Colorectal cancer
Colorectal cancer (CRC) remains a major public health problem and accounts for approximately 13% of all cancers [1, 2] . More effective treatments and earlier detection have led to improved survival over recent decades. However, around 50% of newly diagnosed CRC patients will eventually progress due to micrometastases, and die of their disease. Effective systemic treatments are therefore an important and integral part of the management strategy for CRC.
The background to today's chemotherapy
Progress has undoubtedly been made. Until 1985, 5-fluorouracil (5-FU) was the sole agent available for the treatment of CRC. The response rate (RR) with this drug was around 10%, and median overall survival (OS) 9-11 months. The addition of folinic acid (FA) to bolus 5-FU in the period 1985-1990 made the treatment more active, and improved the RR to 20% [3] . Time to progression (TTP) was prolonged, and OS (more arguably) was improved to 10-12 months. Also in this period, the efficacy of adjuvant chemotherapy in stage III disease was established.
The early 1990s were important for a number of reasons. First, randomized comparisons clearly demonstrated that chemotherapy was indeed improving the condition of patients with metastatic CRC [4, 5] . Secondly, the 1990s saw a major shift (at least in Europe) from bolus to infusional 5-FU, following evidence of improved RR and TTP [6] . Infusional regimens proved able to achieve RRs of up to 30% and median OS of 14 months. This decade also saw the investigation of new drugs and combinations, and the introduction of perioperative chemotherapy.
Since the year 2000 it has proved possible consistently to achieve RRs of 50% and median OS greater than 16 months by using 5-FU/FA in combination with the active new drugs irinotecan and oxaliplatin. Importantly for the future, we are now also seeing the evaluation in CRC of novel agents targeted at molecular processes underlying malignant progression.
Newer cytotoxics alone and with 5-FU
Irinotecan is the first chemotherapy agent to show a survival benefit in second-line CRC, in two randomized trials [7] . Table 1 shows that irinotecan and the oral 5-FU pro-drugs have been able to achieve RRs in the region of 20% and median survival durations of >1 year [7] . These results are comparable to those obtained using bolus 5-FU and FA.
Perhaps more important are the data in Table 2 , which show that the use of irinotecan or oxaliplatin in combinatin with 5-FU/FA ii50 can consistently achieve RRs in the region of 50% and a median OS of 15-16 months or more. In two of these trials, both involving irinotecan, there was a statistically significant benefit when the combination regimen was compared with the 5-FU/FA control arm [8] [9] [10] [11] [12] . Currently, there are no data showing that oxaliplatin in combination with infusional 5FU/FA improves OS when compared with infusional 5-FU/FA alone. In addition to the agents discussed, several other drugs have shown activity in CRC. These include raltitrexed (Tomudex  ® ) , trimetrexate, ethyniluracil, MTA and S1. However, it is likely (at least in the near future) that combination 5-FU/FA regimens will be based on irinotecan or oxaliplatin.
The sequencing of irinotecan and oxaliplatin
The existence of two new and active combination regimens raised the question of their optimal sequencing in first-and in secondline. As is discussed in greater detail elsewhere in this volume, the preferred order appears to be to use the irinotecan-based FOLFIRI (irinotecan/5-FU/leucovorin) regimen followed on progression by the oxaliplatin-based FOLFOX (oxaliplatin/5-FU/leucovorin) combination, rather than the reverse [13] . The TTP with FOLFIRI, used first-line, was 14.4 months versus 11.5 months with FOLFOX (P = 0.65). FOLFIRI (arm A) versus FOLFOX was associated with a lower incidence of potentially serious (grade 3-4) toxicities, i.e. alopecia 24% versus 9% (P <0.05), nausea 13% versus 3% (P <0.05) and stomatitis 10% versus 1% (P <0.05). Grade 3 neurotoxicity was 0% with FOLFIRI first-line and 20% with FOLFOX second-line, versus 34% FOLFOX first-line and 20% FOLFIRI second-line. The overall grade 3-4 toxicity in first-line was 53% versus 74% for FOLFOX, and in second-line 49% versus 56% for FOLFOX. There was also a lower likelihood of patients discontinuing treatment with FOLFIRI used first-line. With both sequences of regimen, RRs were high and median OS was in excess of 20 months. This comparision of irinotecan and oxaliplatin using the same 5-FU regimen demonstrates similar results in terms of RRs and overall TTP after two lines of treatment
Second-line chemotherapy
Progress has also been made in the second-line treatment of patients with CRC. Once again, irinotecan has come to the fore, since use of the drug has been proven to prolong survival significantly compared with either best supportive care alone or best available infusional 5-FU/FA regimens [13] [14] [15] [16] .
Although irinotecan is now considered the standard treatment for patients who have failed 5-FU regimens, a number of other agents have also shown degrees of activity second-line (Table 3 ) [7] . Hence the second-line CRC patient now has the choice not Table 1 . Results achieved first-line in colorectal cancer using newer single agents [7] UFT, uracil/tegafur; RR, response rate. ii51 simply of chemotherapy or no chemotherapy, but of which agent or agents to use. Furthermore, third and even fourth-line chemotherapy becomes possible.
Adjuvant chemotherapy
The standard approach to adjuvant chemotherapy in stage III CRC is to use a bolus (or infusional) 5-FU/FA regimen for 6-8 months [17] . In stage II disease, the evidence of benefit is unclear and adjuvant treatment should be confined to clinical trials. Several ongoing, randomized studies in colon cancer are attempting to define the role of new agents in adjuvant treatment. Thus the PETACC3/V-307 trial is administering either infusional 5-FU/FA alone [according to LV5FU2 or Arbeitsgemeinschaft Internische Onkologie (AIO) schedules] or infusional 5-FU/FA plus irinotecan. The US and NCI Intergroup is comparing weekly bolus 5-FU/FA with weekly bolus 5-FU/FA plus irinotecan, while the French trial compares LV5FU2 alone against the same regimen plus irinotecan. In a second French study, rectal cancer patients at high risk of relapse will receive either irinotecan plus LV5FU2 or the comparative arm (the Mayo clinic regimen or plus LV5FU2).
Neoadjuvant therapy
Use of neoadjuvant therapy offers the possibility of rendering initially unresectable disease amenable to potentially curative surgery, and of reducing the extent of surgery in resectable patients [18] . Long-term survival can be achieved in patients whose liver metastases are resected. The task now is to evaluate the role of chemotherapy in patients with respectable metastases. Phase III trials incorporating newer agents are ongoing.
Emerging prospects
One of the tasks of oncologists is to make treatment appropriate to the circumstances of the patient. The use of factors such as performance status and liver function to judge how well treatment will be tolerated is familiar. More novel is the emergence of aspects of tumor biology that may predict sensitivity to particular drugs. These factors, which may aid the individualization of therapy, include thymidylate synthase, p53 status, DPD, ERCC-1 and microsatellite instability.
The treatment landscape itself may be revolutionized by the emergence of antibodies or small molecules directed at specific molecular targets, such as the epidermal growth factor receptor (EGFR). Data on their use in CRC are still scarce. However, there is interest in the phase II study by Saltz et al. [19] , showing that use of the EGFR antibody cetuximab (IMC-C225) in combination with irinotecan could induce sensitivity to irinotecan in patients refractory to the drug. The RR reported was 22.5% and the median duration of response was 6 months.
Gastric cancer
Gastric cancer represents a challenging problem in oncology and, globally, is one of the most frequent causes of cancer death. Although the incidence of gastric cancer is falling in the Western world, adenocarcinomas of the gastro-esophageal junction are increasing in number [20] [21] [22] .
There have been no major changes in the prognosis of gastric cancer over the last 10-20 years. In advanced disease, the median survival in patients not receiving chemotherapy is 3-4 months. In resectable cancer, surgery is potentially curative. However, the relapse rate is high, and the need for effective systemic therapy is urgent.
Adjuvant chemotherapy and chemoradiotherapy
Taken individually, the majority of studies of adjuvant chemotherapy fail to show a survival benefit [23] . However, these studies tend to have involved relatively low numbers of patients, older chemotherapy regimens [such as 5-FU plus methyllomustine (CCNU) or FAM (5-FU/doxorubicin/mitomycin C)], and heterogeneous populations of patients, including cases of low as well as high risk. There have been a number of metaanalyses of adjuvant chemotherapy studies, with the more recent analyses reporting a significant OS benefit [23] [24] [25] [26] . However, it should be noted that these were not true meta-analyses, but combined analyses.
The major source of data on the effects of combining postoperative chemotherapy with radiotherapy is the recent Intergroup 0116 (SWOG 9008) study [27] . This randomized 603 patients with stage IB-IV (M0) gastric or gastro-esophageal junction carcinomas to surgery alone or surgery followed by 5-FU/FA and radiation. The median disease-free survival was 30 months in the chemoradiotherapy group, and 50% of patients were alive at 3 years. In the control arm, the outcome was significantly less: 19 month disease-free survival and 41% 3-year survival. The effect of combination therapy was essentially to reduce the rate of local failure.
A number of comments should be made about the study. First, surgery was suboptimal in many patients (54% having less than a D1 procedure). It may therefore be that the patients who benefited from chemoradiotherapy were those with inadequate resections. Secondly, it is clear that postoperative chemoradiotherapy requires careful planning and experience. Thirdly, the chemotherapy used in the trial was not optimal by current standards, and there were few stage IB patients (n = 39).
A European Intergroup trial of chemoradiotherapy is at an early stage of planning. One issue to be resolved is whether the control arm should be surgery alone or an 'optimized' SWOG regimen consisting of infusional 5-FU/FA and radiotherapy. A second is whether a more forward-looking chemotherapy regimen (such as 5-FU/FA plus irinotecan) should be employed.
Neoadjuvant therapy
Data from non-randomized phase II and small randomized trials show the feasibility of chemotherapy followed by surgery in patients with locally advanced disease. Since gastric cancer is chemosensitive (with RRs of 30% to 40% reported), downstaging is a realistic hope. Treatment may result in the eradication of micrometastases, and it is likely to be better tolerated before rather than after surgery. To date, there are no data from large, randomized trials, and the selection of patients for any such studies has to be undertaken carefully. The neoadjuvant approach has a clear rationale but should be considered investigational; indeed four controlled trials are in progress. These include the SAKK study of docetaxel plus cisplatin and 5-FU followed by surgery, and the MAGIC study of presurgical ECF (epirubicin/cisplatin/5-FU).
Advanced and metastatic gastric cancer
Four trials in advanced gastric cancer have compared chemotherapy [FEMTX (fluorouracil/epirubicin/methotrexate), FAMTX (5-FU/adriamycin/methotrexate) or ELF (etoposide, leucovorin, 5-fluorouracil)] plus best supportive care versus best supportive care alone (Table 4) [28] [29] [30] [31] . In the control groups, median survivals were 3-5 months, and in the chemotherapy arms 7.5 to 12 months. In three of four studies, the improvement in median OS was significant. In the two studies measuring quality of life, this too was improved by active treatment [30, 31] .
Many studies have compared one chemotherapy regimen against another. These include the EORTC study, which showed that FAMTX was superior to FAM in RR (41% versus 9%) and survival (42 versus 29 weeks) (Table 5 ) [32, 33] . Following a series of studies, including that of Webb et al. [36] demonstrating that ECF led to longer survival than FAMTX (median OS 8.9 versus 5.8 months), it is appropriate to consider some form of 5-FU/platinum combination as a reference regimen in metastatic gastric cancer (Table 6 ) [33] [34] [35] [36] [37] . Such regimens include weekly ECF, weekly or fortnightly 5-FU/FA/cisplatin and monthly 5-FU plus high-dose cisplatin. With these regimens, RRs of 25% to 40% and median OS of 7-9 months can be expected. 
New directions
New cytotoxic agents are being applied to gastric cancer. Singleagent docetaxel used at 80-100 mg/m 2 achieves an RR of ∼20% and 7.5-8 months OS (Table 7 ) [38] [39] [40] [41] [42] . When combined with cisplatin (and possibly also 5-FU), the RRs rise to 33% to 56%, and OS to 9-10 months (Table 7 ) [43] [44] [45] .
Paclitaxel has achieved single-agent RRs ranging from 5% to 23% [45] [46] [47] [48] . In combination with a platinum, RRs of 22% and 63% are reported, and in combination with cisplatin and 5-FU an RR of 50% [49] [50] [51] . Median OS in the three small phase II studies ranged from 8 to 11 months.
Irinotecan has achieved RRs of 19% to 23% as a single agent (Table 8 ) (Wilke, H. J., personal communication) [52] [53] [54] . In combination with cisplatin the RRs rise to 28% to 51%, with median OSs of 7-10 months (Table 8 ) [55] [56] [57] [58] [59] [60] . Irinotecan in combination with CDDP or 5-FU and FA achieved a median survival of more than 10 months [58] .
In a randomized phase III trial, the reference combination of cisplatin with 5-FU is being compared with a regimen consisting of docetaxel plus cisplatin plus 5-FU. In a trial of similar design, 5-FU/FA plus irinotecan will be compared with cisplatin plus 5-FU. Also of interest are the cytostatic agents acting on novel targets. These include the EGFR, vascular endothelial growth factor, matrix metalloproteinases and other tyrosine kinase inhibitors. Trials of the newer cytotoxics in combination with the novel cytostatics can be expected.
